Browse all practice questions for the Menopause Society Practice Exam. Search by topic, open any question and review its full explanation, then test yourself in the practice quiz.

Menopause Society Practice Exam 2026 – The Comprehensive All-in-One Guide to Exam Success! course image
All questions

These questions are part of the practice quiz. Start practicing

  • What is the preferred route of estrogen therapy to reduce thrombosis risk?
  • Are these cognitive changes associated with menopause hormone levels?
  • Osteopenia is defined by what T-score range on DXA?
  • What is the prevalence of arthralgia during the menopause transition?
  • Are compounded bioidentical hormones FDA-approved and standardized in dosing?
  • What lifestyle measures help prevent osteoporosis?
  • How does menopause affect bone density?
  • How does POI affect fertility?
  • Which choice is NOT listed as a lifestyle factor affecting menopausal symptoms?
  • Which condition should be considered as a differential diagnosis for insomnia in menopausal patients?
  • List two non-structural causes of AUB.
  • Which estrogen delivery method is associated with a lower risk of venous thromboembolism and stroke?
  • What is the most common sleep disturbance in menopause?
  • What T-score defines osteoporosis?
  • Which pair represents SERMs used in menopause management?
  • What percentage of midlife women experience arthralgia during the menopause transition?
  • How is body mass index (BMI) used in the evaluation of menopausal weight issues?
  • What marks the postmenopausal period?
  • Which tool is commonly used to estimate 10-year fracture risk in clinical practice?
  • Which STRAW stage is characterized by variable cycle length and increased FSH?
  • Which statement about pelvic organ prolapse is incorrect?
  • The Basson model is primarily used to understand which domain?
  • Which vaccine reduces the risk of cervical cancer?
  • Which of the following are potential risks of surgical menopause?
  • Which statement is true about vaginal estrogen for GSM?
  • What are the most common causes of primary ovarian insufficiency (POI)?
  • What is the FRAX threshold for pharmacologic therapy in terms of 10-year fracture risk?
  • Which hormonal change is associated with the menopause transition?
  • What is the expected duration of the early menopausal transition according to STRAW?
  • What is the primary effect of menopause on bone health?
  • How does a decline in estrogen affect bone health during menopause?
  • Which of the following is a nonhormonal prescription option for vasomotor symptoms?
  • How is osteoporosis defined?
  • Which statement about route of estrogen therapy and thrombosis risk is accurate?
  • Which statement best describes phytoestrogens in menopause?
  • Premature ovarian insufficiency is defined as ovarian failure before what age?
  • Name one primary prevention strategy for cardiovascular disease in midlife women.
  • What are common factors contributing to weight gain during menopause?
  • What is surgical menopause?
  • A T-score of -3.0 indicates which bone health condition?
  • What is the recommended method for assessing central adiposity in cardiovascular risk assessment?
  • What are common components of frailty?
  • Which statement best describes POI in relation to fertility?
  • Which of the following is NOT a commonly described component of frailty?
  • Which of the following is NOT a common side effect of hormone therapy?
  • In hair loss evaluation during menopause, which component is considered an initial step?
  • Which herbal supplement is commonly cited as having insufficient evidence for menopause symptom relief?
  • Name one first-line treatment for metabolic abnormalities in PCOS.
  • How does estrogen deficiency contribute to hair changes in menopause?
  • Which of the following is NOT a STRAW+10 phase?
  • Which non-pharmacologic strategy is recommended for menopausal hair loss?
  • Pelvic floor physical therapy in GSM has been shown to do what?
  • In terms of dietary strategies for bone health, which combination is recommended?
  • Which pharmacologic option is a non-hormonal choice for vasomotor symptoms?
  • In evaluating menopausal sleep changes, which intervention is categorized as a behavioral therapy?
  • Define a luteal out-of-phase (LOOP) event and its clinical significance.
  • Which of the following is a common side effect of systemic hormone therapy?
  • In the PALM-COEIN framework, adenomyosis is categorized as which type of etiology?
  • Which statement about GSM local therapies is true?
  • What is the recommended screening interval for mammography in women aged 50-74?
  • What hormone pattern is typical in POI?
  • Name two measures of ovarian reserve used in the menopause transition.
  • Which of the following is a risk factor for depression in midlife women during menopause?
  • What is the definition of hormone therapy (HT)?
  • Which term describes an abnormal luteal phase with altered hormone secretion?
  • What is the first-line therapy for moderate to severe VMS?
  • Which statement correctly describes a key difference between continuous and sequential hormone therapy regimens?
  • Which are common treatments for menopausal arthralgia?
  • Which of the following is NOT a barrier to care?
  • Which conservative measures are recommended for urinary incontinence?
  • What is a surgical option for weight loss in menopausal women with obesity?
  • What is the prevalence of sexual dysfunction in postmenopausal women?
  • What are risks of surgical menopause?
  • What is the first-line treatment for mild pelvic organ prolapse?
  • Which statement best describes patient education for menopause?
  • Which is a behavioral therapy for sleep changes in menopause?
  • Which of the following are conservative measures for urinary incontinence?
  • How does regular weight-bearing exercise contribute to osteoporosis prevention?
  • What symptoms are commonly associated with LOOP events during perimenopause?
  • Which joints are commonly affected by arthralgia in menopausal women?
  • Which topical option is used for androgenic alopecia in postmenopausal women?
  • What are the benefits of weight-bearing exercise?
  • What is the estimated prevalence of menopause among women aged 45-55 years?
  • Which of the following is a risk factor for depression during menopause?
  • Which sites are used to assess BMD for osteoporosis diagnosis per WHO criteria?
  • Which of the following is a structural cause of AUB?
  • Which statement about hair loss patterns observed in menopause is accurate?
  • Which statement is true about sleep disturbances and menopause?
  • Which of the following is a non-structural cause of AUB?
  • What is the initial step in evaluating AUB?
  • In POI, HT is used to relieve symptoms and prevent osteoporosis.
  • Which statement is true about GSM treatment?
  • What is the risk of venous thromboembolism with hormone therapy?
  • What is the gold standard test to diagnose osteoporosis?
  • Which imaging modality is not considered first-line for evaluating abnormal uterine bleeding?
  • What dietary pattern supports bone health in postmenopausal women?
  • For postmenopausal bone health, what is the recommended combination of calcium and vitamin D?
  • What laboratory test is essential in all women presenting with abnormal uterine bleeding?
  • What is bioidentical hormone therapy?
  • Endometrial biopsy in AUB is indicated in which scenario?
  • Which of the following is an example of a nonhormonal pharmacologic therapy for VMS?
  • What is the evidence for compounded bioidentical hormones?
  • What is the recommended vitamin D intake?
  • How does the menopause transition differ from postmenopause in terms of hormonal changes?
  • What is tibolone and in what context is it used?
  • What is the role of hormone therapy in POI?
  • Which statement best describes recommended patient education for menopause?
  • What is the definition of surgical menopause?
  • Name two local therapies for GSM.
  • Name one nonhormonal pharmacologic therapy for VMS.
  • Which of the following is a non-pharmacologic approach to managing menopausal symptoms?
  • Which of the following is NOT a barrier to care for menopausal women?
  • PCOS is associated with increased risk of which cardiovascular/metabolic conditions?
  • What is the evidence for the efficacy of over-the-counter herbal supplements in menopause symptom relief?
  • Which of the following is a surgical option for severe pelvic organ prolapse?
  • Which statement about first-line medical therapy for AUB is correct?
  • What is the term for the interval of hormonal fluctuation and menstrual irregularity before menopause?
  • Which statement about GSM?
  • In sequential therapy, progestogen is taken for how many days per month typically?
  • What is the role of hormone therapy in the prevention of postmenopausal osteoporosis?
  • What is the recommended daily intake of calcium and vitamin D for postmenopausal women?
  • Name three major risk factors for low bone mass and fracture in postmenopausal women.
  • What is the most common cardiovascular disease in postmenopausal women?
  • PCOS is associated with increased risk of which cardiovascular/metabolic conditions?
  • Which of the following is not considered a first-line pharmacologic therapy for osteoporosis?
  • Which statement correctly describes the PALM-COEIN framework?
  • What is the role of vaginal moisturizers and lubricants in managing genitourinary syndrome of menopause (GSM)?
  • What is the role of progestin in hormone therapy?
  • The Basson model is a model of which aspect relevant to menopause?
  • What is the relationship between menopause and sleep apnea?
  • Polycystic ovary syndrome is best described as which combination?
  • What is the role of pelvic floor physical therapy in genitourinary syndrome of menopause?
  • Which statement best describes the role of menopausal hormone therapy in cardiovascular disease prevention?
  • Which condition is a differential diagnosis for insomnia in menopause?
  • Which class of drugs is commonly used to treat osteoporosis?
  • Which cancers have screening recommendations relevant to menopausal women?
  • What is the impact of menopause on quality of life?
  • What is the effect of hormone therapy on cardiovascular disease risk?
  • Which of the following is NOT a barrier to care?
  • Which option is NOT a recommended focus of menopause education?
  • Which symptom prompts evaluation for endometrial hyperplasia or cancer?
  • Which pharmacologic agent is preferred for women at very high risk of fracture?
  • Why is progestogen added to estrogen therapy in women who have an intact uterus?
  • Which sites are most commonly affected by osteoporotic fractures?
  • What is the effect of smoking on menopause?
  • Which two cancer treatments can induce menopause?
  • SERMs are used for which purposes?
  • Which factor is NOT commonly associated with weight gain during menopause?
  • Which local therapy is recommended for genitourinary syndrome of menopause?
  • Which of the following are risk factors for urinary incontinence in midlife women?
  • Which drug is an anabolic agent used in osteoporosis management?
  • Which of the following is a SERM used in menopause management?
  • What is the typical duration of hormone therapy?
  • HT in POI is recommended until the average age of menopause.
  • What is the mean age of natural menopause in the United States?
  • What lifestyle factors affect menopausal symptoms?
  • Hormone therapy that combines estrogen with progestin has been linked to increased risk of which condition?
  • Name one medication class used to treat osteoporosis.
  • Which hormonal changes during menopause are associated with reduced libido, arousal, and vaginal lubrication?
  • Name three common sexually transmitted infections relevant to midlife women.
  • What is the first-line imaging modality for evaluating AUB?
  • Which STRAW stage follows the reproductive phase?
  • Which of the following is NOT a barrier to care for menopausal women?
  • In the PALM-COEIN framework, which is a structural etiology?
  • What cognitive changes are reported in midlife women?
  • Define arthralgia.
  • What is the impact of androgen decline on sexual function in menopausal women?
  • What is the recommended role for hormone therapy in women with POI?
  • Which statement best describes non-hormonal management of vasomotor symptoms?
  • Approximately what percentage of women experience VMS during menopause?
  • Arthralgia during menopause is most closely associated with which hormonal change?
  • Which item should be included in patient education about menopause?
  • Local estrogen therapy is especially helpful for which symptom cluster in menopause?
  • What does FRAX combine to estimate 10-year fracture risk?
  • Frailty risk in midlife increases with aging and deficiency of which hormone?
  • Between which ages is menopause most likely to occur?
  • What are treatment goals in POI?
  • Which combination lists correct risk factors for urinary incontinence in midlife women?
  • Name two clinical consequences of early estrogen loss.
  • What is genitourinary syndrome of menopause (GSM)?
  • Abnormal uterine bleeding in peri/menopause may be a sign of what?
  • What is the median duration of VMS?
  • Name two first-line pharmacologic therapies for osteoporosis in postmenopausal women.
  • Which statement about pelvic organ prolapse risk factors is true?
  • What is the role of cognitive behavioral therapy (CBT) in menopause?
  • List two structural causes of AUB.
  • Sacrocolpopexy is a surgical option for which condition?
  • Which statement about osteoporosis prevention is true?
  • Which statement about hypertension risk after menopause is true?
  • Which of the following is a nonhormonal prescription option for vasomotor symptoms (example: SNRI)?
  • What is the effect of hormone therapy on bone?
  • Which statement best describes the risks of compounded or non-approved hormone therapy preparations?
  • Which immunizations are recommended for midlife women to reduce morbidity?
  • A comprehensive menopause education plan should cover which of the following?
  • Name a first-line medical therapy for AUB.
  • What is the role of selective estrogen receptor modulators (SERMs)?
  • Which statement best describes the overall impact of menopause on cardiovascular risk?
  • List three causes of secondary amenorrhea in women under 40.
  • Which intervention is described as first-line for metabolic abnormalities in PCOS?
  • Which combination is used in hormone therapy for menopausal symptoms?
  • Name three risk factors for AUB in midlife women.
  • What is the clinical definition of menopause?
  • How is arthralgia related to estrogen decline?
  • Which of the following is an absolute contraindication to hormone therapy?
  • List the three main phases defined by the STRAW+10 staging system.
  • After menopause, which lipid parameter tends to decrease?
  • Endometrial biopsy is indicated in AUB for which scenario?
  • How is abnormal uterine bleeding defined?
  • Which statement best describes dosing for hormone therapy?
  • Which of the following are common symptoms of pelvic organ prolapse?
  • Which are common side effects of hormone therapy?
  • Which option is NOT a barrier to care for menopausal women?
  • Local estrogen therapy may improve which menopausal symptoms?
  • Which classification system is used for AUB etiologies?
  • Which of the following is NOT a barrier to care for menopausal women?
  • What is an effect of hormone therapy on sexual function in postmenopausal women?
  • What is the definition of frailty?
  • What is the role of pelvic floor physical therapy in managing sexual dysfunction in menopause?
  • Which of the following is a risk factor for pelvic organ prolapse?
  • Hormone therapy in women with POI is recommended for symptom relief and bone protection until approximately what age?
  • Which physical examination findings are important when evaluating abnormal uterine bleeding (AUB)?
  • How does the prevalence of hypertension change after menopause?
  • Which of the following is a surgical option for weight loss in menopausal women with obesity?
  • What is a potential health outcome of untreated sleep disturbance in menopause?
  • Which statement best describes STRAW+10 staging system?
  • What is the initial step in evaluating hair loss during menopause?
  • What symptoms define vasomotor symptoms (VMS)?
  • Tibolone is best described as what kind of agent?
  • Systemic hormone therapy should be reassessed annually.
  • What is the recommended duration of systemic hormone therapy for vasomotor symptoms?
  • In midlife women with PCOS, which features are commonly present?
  • Which symptom is commonly associated with perimenopause?
  • Which statement best describes VMS prevalence and duration?
  • Which hormone therapy is associated with an increased risk of breast cancer?
  • Which combination of vaccines is recommended for midlife women to reduce morbidity?
  • What is the risk of cardiovascular disease in POI?
  • Which is a key goal of menopause patient education?
  • Name one general risk factor for cardiovascular disease in midlife women.
  • Name a surgical option for refractory AUB.
  • What is the first-line lifestyle intervention for weight management in menopause?
  • What is pelvic organ prolapse?
  • Which two conditions are risk factors for sleep changes in menopausal women?
  • Which option is NOT a barrier to care?
  • GSM is most directly caused by what deficiency?
  • Which of the following is an iatrogenic cause of POI?
  • According to WHO criteria, osteoporosis is defined by a T-score ≤ -2.5 at which sites?
  • Name one FDA-approved pharmacologic therapy for weight loss in postmenopausal women.
  • Urinary incontinence is defined as what?
  • Name two types of hair loss seen in menopausal women.
  • What is the prevalence of AUB in perimenopausal women?
  • Which screening test is recommended for thyroid disease in symptomatic or high-risk midlife women?
  • Which topics are appropriate to include in menopause patient education?
  • Which factor influences the cardiovascular risk associated with hormone therapy?
  • What are key metabolic concerns in PCOS?
  • Which of the following is NOT a barrier to care for menopausal women?
  • Which two types of urinary incontinence are commonly recognized?
  • Which two non-pharmacologic strategies are cited for managing vasomotor symptoms?
  • Which statement best describes non-pharmacological interventions for vasomotor symptoms?
  • What lipid pattern is typically seen after menopause?
  • Which statement is true about Orlistat as a weight-loss therapy for postmenopausal women?
  • What are the dominant symptoms during the late menopausal transition?
  • Which drug class includes alendronate, risedronate, and zoledronic acid?
  • What is the recommended calcium intake for postmenopausal women?
  • Which statement about frailty is true?
  • What is the age threshold for routine DXA screening in postmenopausal women, according to the North American Menopause Society?
  • What is the approximate prevalence of depression during the menopause transition?
  • In STRAW+10, postmenopause refers to which time period?
  • Which option is NOT a common cause of POI?
  • Which of the following is a key metabolic concern in PCOS?
  • What screening tools are validated for intimate partner violence in midlife women?
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy